NCT06586866View on ClinicalTrials.gov

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

May 26, 2026

Study Completion Date

October 26, 2026

Conditions
Triple Negative Breast Cancer (TNBC)Brain Metastasases
Interventions
DRUG

JK-1201I

JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.

All Listed Sponsors
lead

JenKem Technology Co., Ltd.

INDUSTRY

NCT06586866 - JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases | Biotech Hunter | Biotech Hunter